285 related articles for article (PubMed ID: 16306595)
21. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.
Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM
Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388
[TBL] [Abstract][Full Text] [Related]
22. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses.
De BP; Heguy A; Hackett NR; Ferris B; Leopold PL; Lee J; Pierre L; Gao G; Wilson JM; Crystal RG
Mol Ther; 2006 Jan; 13(1):67-76. PubMed ID: 16260185
[TBL] [Abstract][Full Text] [Related]
23. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing.
Adachi K; Enoki T; Kawano Y; Veraz M; Nakai H
Nat Commun; 2014; 5():3075. PubMed ID: 24435020
[TBL] [Abstract][Full Text] [Related]
24. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
[TBL] [Abstract][Full Text] [Related]
25. Complement is an essential component of the immune response to adeno-associated virus vectors.
Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
[TBL] [Abstract][Full Text] [Related]
26. A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors.
Davis-Gardner ME; Weber JA; Xie J; Pekrun K; Alexander EA; Weisgrau KL; Furlott JR; Rakasz EG; Kay MA; Gao G; Farzan M; Gardner MR
Front Immunol; 2023; 14():1105617. PubMed ID: 37153616
[TBL] [Abstract][Full Text] [Related]
27. A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid.
Qiu J; Brown KE
Virology; 1999 May; 257(2):373-82. PubMed ID: 10329548
[TBL] [Abstract][Full Text] [Related]
28. An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.
Dudek AM; Pillay S; Puschnik AS; Nagamine CM; Cheng F; Qiu J; Carette JE; Vandenberghe LH
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343568
[TBL] [Abstract][Full Text] [Related]
29. Mutants at the 2-Fold Interface of Adeno-associated Virus Type 2 (AAV2) Structural Proteins Suggest a Role in Viral Transcription for AAV Capsids.
Aydemir F; Salganik M; Resztak J; Singh J; Bennett A; Agbandje-McKenna M; Muzyczka N
J Virol; 2016 Aug; 90(16):7196-7204. PubMed ID: 27252527
[TBL] [Abstract][Full Text] [Related]
30. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
[TBL] [Abstract][Full Text] [Related]
31. Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea.
Frederick A; Sullivan J; Liu L; Adamowicz M; Lukason M; Raymer J; Luo Z; Jin X; Rao KN; O'Riordan C
Hum Gene Ther; 2020 Jul; 31(13-14):756-774. PubMed ID: 32578442
[TBL] [Abstract][Full Text] [Related]
32. Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.
Castle MJ; Turunen HT; Vandenberghe LH; Wolfe JH
Methods Mol Biol; 2016; 1382():133-49. PubMed ID: 26611584
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity.
Mietzsch M; Hull JA; Makal VE; Jimenez Ybargollin A; Yu JC; McKissock K; Bennett A; Penzes J; Lins-Austin B; Yu Q; Chipman P; Bhattacharya N; Sousa D; Strugatsky D; Tijssen P; McKenna R; Agbandje-McKenna M
J Virol; 2022 Jun; 96(11):e0033522. PubMed ID: 35532224
[TBL] [Abstract][Full Text] [Related]
34. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.
Yang L; Jiang J; Drouin LM; Agbandje-McKenna M; Chen C; Qiao C; Pu D; Hu X; Wang DZ; Li J; Xiao X
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3946-51. PubMed ID: 19234115
[TBL] [Abstract][Full Text] [Related]
35. High-Resolution Structural Characterization of a New Adeno-associated Virus Serotype 5 Antibody Epitope toward Engineering Antibody-Resistant Recombinant Gene Delivery Vectors.
Jose A; Mietzsch M; Smith JK; Kurian J; Chipman P; McKenna R; Chiorini J; Agbandje-McKenna M
J Virol; 2019 Jan; 93(1):. PubMed ID: 30333169
[TBL] [Abstract][Full Text] [Related]
36. The role of the adeno-associated virus capsid in gene transfer.
Van Vliet KM; Blouin V; Brument N; Agbandje-McKenna M; Snyder RO
Methods Mol Biol; 2008; 437():51-91. PubMed ID: 18369962
[TBL] [Abstract][Full Text] [Related]
37. AAV Vectors Pseudotyped with Capsids from Porcine and Bovine Species Mediate In Vitro and In Vivo Gene Delivery.
Yu DL; van Lieshout LP; Stevens BAY; Near KJJ; Stodola JK; Stinson KJ; Slavic D; Wootton SK
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257756
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.
Grimm D; Lee JS; Wang L; Desai T; Akache B; Storm TA; Kay MA
J Virol; 2008 Jun; 82(12):5887-911. PubMed ID: 18400866
[TBL] [Abstract][Full Text] [Related]
39. Optimization of AAV vectors to target persistent viral reservoirs.
Colón-Thillet R; Jerome KR; Stone D
Virol J; 2021 Apr; 18(1):85. PubMed ID: 33892762
[TBL] [Abstract][Full Text] [Related]
40. Adeno-associated viral vectors and their redirection to cell-type specific receptors.
Michelfelder S; Trepel M
Adv Genet; 2009; 67():29-60. PubMed ID: 19914449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
